Postmarketing surveillance study of Norplant in developing countries

Lancet

Volumn 357, Issue 9271, 2001, Pages 1815-1816

  Hannaford, Philip ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVONORGESTREL;

CONTRACEPTION; CONTROLLED DRUG RELEASE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECTOPIC PREGNANCY; FAMILY PLANNING; HEALTH; HEALTH HAZARD; HUMAN; IMPLANT; INSTRUMENT STERILIZATION; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDICAL EXAMINATION; NOTE; POPULATION; PREGNANCY; PRIORITY JOURNAL; RACE DIFFERENCE;

EID: 0035832524     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)05007-8     Document Type: Note

References (9)

1. Overpopulation and overconsumption
2. Norplant consensus statement and background review
3. The "Boom and bust phenomenon": The hopes, dreams, and broken promises of the contraceptive revolution
4. The case of Norplant as an example of media coverage over the life of a new health technology
5. Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization
6. Clinical performance of a new two-rod levonorgestrel contraceptive implant: A three-year randomized study with Norplant implants as controls
7. Levonorgestrel capsule implants in the United States: A 5-year study
8. A 10-year follow-up study of contraceptive Norplant implants